MedeliX
Start asking

Emtricitabine/tenofovir disoproxil

Truvada · ATC code J05AR03

Also known as: Emtricitabin/Tenofovirdisoproxil, Emtrisitabin/tenofovir disoproksil, Emtricitabina / tenofovir disoproxil, Emtricitabine / ténofovir disoproxil, Emtricitabina / tenofovir disoproxilo, Emtricitabine / Tenofovir Disoproxil · Brand names: Truvada, Emtenovo, Emtricitabin Tenofovirdisoproxil Zentiva, Emtricitabin/Tenofovirdisoproxil Abdi, Emtricitabin/Tenofovirdisoproxil Al, Emtricitabin/Tenofovirdisoproxil Amarox, Emtricitabin/Tenofovirdisoproxil Beta, Emtricitabin/Tenofovirdisoproxil Cipla, Emtricitabin/Tenofovirdisoproxil Heumann, Emtricitabin/Tenofovirdisoproxil Hormosan, Emtricitabin/Tenofovirdisoproxil Puren, Emtricitabin/Tenofovirdisoproxil Ratiopharm, Oremten, Emtricitabin/Tenofovir Sandoz, Emtricitabin/Tenofovirdisoproxil Stada …

Key facts
Active substance
Emtricitabine/tenofovir disoproxil (INN: emtricitabine / tenofovir disoproxil)
Drug class
Efavirenz/lamivudine/tenofovir
ATC code
J05AR03
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Truvada 200 mg/245 mg film-coated tablets
Marketing authorisation holder
Gilead Sciences Ireland UC
Information as of
2026-10-27

Key facts

Emtricitabine/tenofovir disoproxil combines two nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV-1 infection and pre-exposure prophylaxis (PrEP).

What it is used for

  • Treatment of HIV-1 infection in adults as part of antiretroviral combination therapy
  • HIV-1 infected adolescents when NRTI resistance or toxicities preclude first-line agents
  • PrEP combined with safer sex practices in adults and adolescents at high risk

Dosing

  • Treatment and PrEP (aged 12 and older, at least 35 kg): one tablet once daily
  • Missed dose within 12 hours: take as soon as possible; vomiting within 1 hour: take another tablet
  • Treatment with CrCl 30-49 mL/min: every 48 hours; CrCl < 30 mL/min and haemodialysis: not recommended
  • PrEP not recommended with CrCl < 60 mL/min
  • No dose adjustment in the elderly or hepatic impairment

Contraindications

  • Hypersensitivity to the active substances or any excipient
  • PrEP in individuals with unknown or positive HIV-1 status

Important warnings

  • PrEP only in confirmed HIV-negative individuals, re-tested frequently, as resistance can emerge
  • PrEP only as part of an overall prevention strategy, e.g. condom use and STI testing
  • Renal impairment up to renal failure and Fanconi syndrome; creatinine clearance before starting and regularly
  • Bone abnormalities such as osteomalacia and reduced bone mineral density
  • HBV co-infection: severe exacerbations of hepatitis possible after discontinuation

Side effects

  • HIV treatment: most frequently nausea and diarrhoea
  • PrEP: headache most frequent; no new adverse reactions
  • Renal effects and bone abnormalities with tenofovir disoproxil

Interactions

  • Not with other products containing emtricitabine, tenofovir disoproxil, tenofovir alafenamide or cytidine analogues such as lamivudine
  • Not with adefovir dipivoxil
  • Low potential for CYP450-mediated interactions

Pregnancy and breastfeeding

  • A large amount of data shows no malformations; use in pregnancy may be considered if necessary
  • Not during breast-feeding; women living with HIV are advised not to breast-feed

Summary of the official product information, written with AI on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Germany

  • EmtenovoTad Pharma Gmbh · 1 register entry
  • Emtricitabin Tenofovirdisoproxil ZentivaZentiva Pharma Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil AbdiAbdi Farma Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil AlAliud Pharma Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil AmaroxAmarox Pharma Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil BetaBetapharm Arzneimittel Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil CiplaCipla Europe Nv · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil HeumannHeumann Pharma Gmbh & Co. Generica Kg · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil HormosanHormosan Pharma Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil PurenPuren Pharma Gmbh & Co. Kg · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil RatiopharmRatiopharm Gmbh · 1 register entry
  • OremtenOresund Pharma Aps · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Austria

  • Emtricitabin/Tenofovir SandozSandoz Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil StadaStada Arzneimittel Gmbh · 1 register entry
  • Emtricitabin/Tenofovirdisoproxil TillomedTillomed Pharma Gmbh · 1 register entry
  • Emtricitabine/Tenofovir Disoproxil AccordpharmaAccord Healthcare B.V. · 1 register entry
  • Emtricitabine/Tenofovir Disoproxil RatiopharmTeva B.V · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • HiventİLKO İLAÇ SAN.VE TİC. A.Ş. · 2 register entries
  • PernoiSANOVEL İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • SidatriaSANOFİ İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • TruventHUMANİS SAĞLIK A.Ş. · 2 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 23 more European countries
Belgium
Emtricitabin/Tenofovir Disoproxil Ab
Croatia
Emtricitabin/Tenofovirdizoproksil Pliva
Cyprus
Exatron
Denmark
Emtricitabin/Tenofovirdisoproxil Tillomed, Emtricitabine/Tenofovir Disoproxil "sandoz", Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Glenmark, Emtricitabine/Tenofovir Disoproxil Stada, Emtricitabine/Tenofovir Disoproxil Teva, Oremten
Estonia
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Teva, Emtricitabine/Tenofovir Zentiva
Finland
Emtricitabine / Tenofovir Disoproxil Stada, Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Tillomed
France
Emtricitabine/ Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Accord, Emtricitabine/Tenofovir Disoproxil Arrow, Emtricitabine/Tenofovir Disoproxil Biogaran, Emtricitabine/Tenofovir Disoproxil Cipla, Emtricitabine/Tenofovir Disoproxil Eg, Emtricitabine/Tenofovir Disoproxil Evolugen, Emtricitabine/Tenofovir Disoproxil Teva, Emtricitabine/Tenofovir Disoproxil Zentiva Lab, Emtricitabine/Tenofovir Disoproxil Zydus
Greece
Argiodin, Emtricitabin/Tenofovir Disoproxil Accord, Valdevon
Hungary
Dunotrisin, Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir-Disoproxil Teva, Tabinera
Iceland
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Krka, Emtricitabine/Tenofovir Disoproxil Mylan, Emtricitabine/Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Zentiva, Truvada
Ireland
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Clonmel, Emtricitabine/Tenofovir Disoproxil Teva, Emtricitabine/Tenofovir Disoproxil Tillomed
Italy
Emtricitabina E Tenofovir Disoproxil Aequilibrium Pharma, Emtricitabina E Tenofovir Disoproxil Aurobindo, Emtricitabina E Tenofovir Disoproxil Doc Generici, Emtricitabina E Tenofovir Disoproxil Teva
Latvia
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Teva, Emtricitabine/Tenofovir Disoproxil Unifarma
Liechtenstein
Emtricitabine/Tenofovir Disoproxil Mylan, Emtricitabine/Tenofovir Disoproxil Zentiva, Truvada
Lithuania
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Sandoz
Netherlands
Emtricitabine Tenofovir Disoproxyl Fumarate Aurobindo, Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovirdisoproxil Accord, Emtricitabine/Tenofovirdisoproxil Amarox, Emtricitabine/Tenofovirdisoproxil Doc Generici, Emtricitabine/Tenofovirdisoproxil Glenmark, Emtricitabine/Tenofovirdisoproxil Sandoz, Emtricitabine/Tenofovirdisoproxil Teva, Emtricitabine/Tenofovirdisoproxil Tillomed, Valdevon
Norway
Emtricitabin/Tenofovirdisoproxil Tillomed, Emtricitabine/ Tenofovir Disoproxil Cipla, Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Krka, Emtricitabine/Tenofovir Disoproxil Mylan, Emtricitabine/Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Zentiva, Truvada
Poland
Emtricitabine + Tenofovir Disoproxil Aurovitas, Emtricitabine + Tenofovir Disoproxil Tillomed
Portugal
Emtricitabina + Tenofovir Accord, Emtricitabina + Tenofovir Disoproxil, Emtricitabina + Tenofovir Farmoz, Emtricitabina + Tenofovir Generis, Emtricitabina + Tenofovir Teva, Emtricitabina + Tenofovir Zentiva
Romania
Emtricitabină/Tenofovir Disoproxil Stada, Emtricitabină/Tenofovir Disoproxil Teva, Emtricitabină/Tenofovir Disoproxil Tillomed
Slovenia
Emtricitabin/Dizoproksiltenofovirat Teva
Spain
Emtricitabina/Tenofovir Disoproxilo Aurovitas, Emtricitabina/Tenofovir Disoproxilo Glenmark, Emtricitabina/Tenofovir Disoproxilo Macleods, Emtricitabina/Tenofovir Disoproxilo Tillomed, Emtricitabine/Tenofovir Disoproxil Teva
Sweden
Emtricitabine/Tenofovir Disoproxil Accordpharma, Emtricitabine/Tenofovir Disoproxil Glenmark, Emtricitabine/Tenofovir Disoproxil Sandoz, Emtricitabine/Tenofovir Disoproxil Stada, Emtricitabine/Tenofovir Disoproxil Teva, Emtricitabine/Tenofovir Disoproxil Tillomed, Oremten

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Truvada – EPAR, Product Information. 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/truvada-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC J05AR.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.